A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00001805
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase II clinical and pharmacokinetic study of suppression of human antimouse (HAMA) and antitoxin antibodies (HATA) to immunotoxin LMB-1 by Rituximab (anti-CD20). The primary objective of this study is to determine the effect of Rituximab on HAMA and HATA response to LMB-1 administered to patients with advanced carcinoma that express the B3 antigen. Other objectives include evaluation of the pharmacokinetics and anti-tumor effects.

Key Dates

Start date
Mar 31, 1999
Status verified
Mar 2000
Completion
Jun 30, 2000

Study Design

Enrollment
20 participants
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
National Cancer Institute (NCI)BethesdaMaryland20892-

Find similar trials in Bethesda, MD

By condition
Breast cancerLung cancer
By specialty
OncologyBreast oncologyWomen's healthLung oncologyLung disease
By research site
National Cancer Institute (NCI)· Bethesda, MD

Related Studies